We’ll help you find the highest quality medicine that you need.

Pomalyst

is indicated for patients with multiple myeloma who have received at least two prior therapies including Lenalidomide and Bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Manufactured by: Celgene Corp

Active Ingredient(s): Pomalidomide

Dosage Form: Capsule, oral

Strength: 1 mg, 2 mg, 3 mg and 4 mg

FDA approved: February 8, 2013

More information about Pomalyst:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204026lbl.pdf

https://www.celgene.com/content/uploads/pomalyst-pi.pdf

Interested in a product you don’t see? Please contact us with an inquiry. We may be able to find it for you.